Literature DB >> 10603169

Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1.

C J Briggs1, D E Ott, L V Coren, S Oroszlan, J Tözsér.   

Abstract

The presence of FK506-binding protein-12 was demonstrated in virions of HIV-1, although its concentration was lower than that of cyclophilin A. The effect of two inhibitors of the peptidyl-prolyl cis-trans isomerases FK506 and cyclosporin A (CsA) was studied in H9 cells that were chronically infected by HIV-1. Both drugs inhibited virus production in the infected cells in a concentration-dependent manner, by decreasing the number of the producing cells. FK506 did not have an effect on Gag processing, based on the p24 antigen content of virions produced in the presence of this drug. Furthermore, FK506 treatment of uninfected H9 cells did not diminish their susceptibility toward HIV-1 infection, whereas CsA treatment decreased the degree of HIV-1 infection with an IC(50) of 1-2 microg/ml. Also, pretreatment of the virus with CsA decreased its infectivity in HeLaCD4-LTR/beta-gal cells; in contrast, at concentrations up to 10 microg/ml, FK506 did not have an effect. Our findings on the antiviral activity of FK506 and CsA suggest that FK506 is effective only in chronically infected cells, by selectively inhibiting the growth of HIV-1 infected cells, whereas CsA has a specific effect on virus replication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10603169     DOI: 10.1007/s007050050629

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  9 in total

Review 1.  Plunder and stowaways: incorporation of cellular proteins by enveloped viruses.

Authors:  Réjean Cantin; Sylvie Méthot; Michel J Tremblay
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Cyclosporin A inhibits the replication of diverse coronaviruses.

Authors:  Adriaan H de Wilde; Jessika C Zevenhoven-Dobbe; Yvonne van der Meer; Volker Thiel; Krishna Narayanan; Shinji Makino; Eric J Snijder; Martijn J van Hemert
Journal:  J Gen Virol       Date:  2011-07-13       Impact factor: 3.891

3.  Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis.

Authors:  Adriaan H de Wilde; Yanhua Li; Yvonne van der Meer; Grégoire Vuagniaux; Robert Lysek; Ying Fang; Eric J Snijder; Martijn J van Hemert
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 4.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Authors:  Julie Dyall; Robin Gross; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Lisa E Hensley; Matthew B Frieman; Peter B Jahrling
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

5.  Cyclophilin A enables specific HIV-1 Tat palmitoylation and accumulation in uninfected cells.

Authors:  Christophe Chopard; Phuoc Bao Viet Tong; Petra Tóth; Malvina Schatz; Hocine Yezid; Solène Debaisieux; Clément Mettling; Antoine Gross; Martine Pugnière; Annie Tu; Jean-Marc Strub; Jean-Michel Mesnard; Nicolas Vitale; Bruno Beaumelle
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 14.919

6.  Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506.

Authors:  Javier Carbajo-Lozoya; Marcel A Müller; Stephan Kallies; Volker Thiel; Christian Drosten; Albrecht von Brunn
Journal:  Virus Res       Date:  2012-02-10       Impact factor: 3.303

Review 7.  Virus-host interactomes--antiviral drug discovery.

Authors:  Yue Ma-Lauer; Jian Lei; Rolf Hilgenfeld; Albrecht von Brunn
Journal:  Curr Opin Virol       Date:  2012-10       Impact factor: 7.090

Review 8.  Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?

Authors:  Christian A Devaux; Cléa Melenotte; Marie-Dominique Piercecchi-Marti; Clémence Delteil; Didier Raoult
Journal:  Front Med (Lausanne)       Date:  2021-09-06

Review 9.  Unraveling Nutritional Regulation of Tacrolimus Biosynthesis in Streptomyces tsukubaensis through omic Approaches.

Authors:  María Ordóñez-Robles; Fernando Santos-Beneit; Juan F Martín
Journal:  Antibiotics (Basel)       Date:  2018-05-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.